Billiontoone (NASDAQ:BLLN) Shares Gap Down – Should You Sell?

Billiontoone, Inc. (NASDAQ:BLLN) shares gapped down before the market opened on Tuesday . The stock had previously closed at $105.94, but opened at $98.26. Billiontoone shares last traded at $100.7940, with a volume of 180,266 shares trading hands.

Analysts Set New Price Targets

BLLN has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Billiontoone in a research note on Friday, May 1st. Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. lifted their price target on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. BTIG Research lowered their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Wells Fargo & Company lowered their price target on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research report on Thursday, March 5th. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $125.29.

Billiontoone Stock Down 2.9%

The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. The company’s fifty day moving average is $79.71. The company has a market capitalization of $4.04 billion and a PE ratio of 159.89.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $95.81 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. The firm’s revenue for the quarter was up 83.8% on a year-over-year basis. As a group, analysts predict that Billiontoone, Inc. will post 0.93 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio purchased a new position in shares of Billiontoone during the first quarter valued at approximately $1,539,000. Sei Investments Co. purchased a new position in shares of Billiontoone during the first quarter valued at approximately $1,058,000. Emerald Mutual Fund Advisers Trust grew its position in Billiontoone by 11.9% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock valued at $10,436,000 after buying an additional 14,072 shares during the period. Emerald Advisers LLC grew its position in Billiontoone by 26.8% during the first quarter. Emerald Advisers LLC now owns 239,562 shares of the company’s stock valued at $18,911,000 after buying an additional 50,613 shares during the period. Finally, Wasatch Advisors LP bought a new stake in Billiontoone during the first quarter valued at approximately $29,179,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.